Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Finished Goods (2017 - 2019)

Ironwood Pharmaceuticals (IRWD) has disclosed Finished Goods for 3 consecutive years, with $191000.0 as the latest value for Q4 2019.

  • Quarterly Finished Goods changed N/A to $191000.0 in Q4 2019 from the year-ago period, while the trailing twelve-month figure was $191000.0 through Dec 2019, changed N/A year-over-year, with the annual reading at $191000.0 for FY2019, N/A changed from the prior year.
  • Finished Goods hit $191000.0 in Q4 2019 for Ironwood Pharmaceuticals, down from $457000.0 in the prior quarter.
  • In the past five years, Finished Goods ranged from a high of $1.4 million in Q1 2018 to a low of $76000.0 in Q3 2018.
  • Historically, Finished Goods has averaged $589428.6 across 3 years, with a median of $479000.0 in 2017.
  • Biggest five-year swings in Finished Goods: crashed 84.13% in 2018 and later surged 501.32% in 2019.
  • Year by year, Finished Goods stood at $735000.0 in 2017, then crashed by 89.66% to $76000.0 in 2018, then soared by 151.32% to $191000.0 in 2019.
  • Business Quant data shows Finished Goods for IRWD at $191000.0 in Q4 2019, $457000.0 in Q3 2019, and $76000.0 in Q3 2018.